Revolutionary new cancer treatment approved in US

The leukemia treatment is based on a type of potent gene-modifying immunotherapy

This undated image made available by Novartis shows an IV bag of their drug Kymriah. Photograph: Novartis via AP
This undated image made available by Novartis shows an IV bag of their drug Kymriah. Photograph: Novartis via AP

The US Food and Drug Administration (FDA) on Wednesday gave a green light to Novartis AG's leukemia treatment, marking the first time that a highly-anticipated new type of potent gene-modifying immunotherapy has gained approval in the US.

The treatment, to be sold under the name Kymriah, was approved for patients up to 25-years-old who have relapsed or were not helped by initial treatment for B-cell acute lymphoblastic leukemia.

Kymriah belongs to a new class of drugs called chimeric antigen receptor T-cell, or CAR T-cell, therapy.

The treatment involves removing disease-fighting T-cells from a patient, genetically modifying them to better recognise and fight cancer and then replacing them in the patient, where they can circulate for years seeking out the disease.

READ MORE

‘New frontier’

“We’re entering a new frontier in medical innovation with the ability to reprogramme a patient’s own cells to attack a deadly cancer,” FDA commissioner Scott Gottlieb said in a statement.

Novartis has not yet announced the cost for the therapy, but British health authorities have said a price of $649,000 (€546,000) for a one-time treatment would be justified given the significant benefits, according to a Kaiser Health News report last week.

Reuters